|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Wang Chiung Chih | Lee Duen | Wang Chiung Chih | (02)2325-2008 | Suite 102, Cannon Place, North Sound Rd., George Town,P.O. Box 712,Grand Cayman, KY1-9006, Cayman Islands | 2013/01/30 | |||
Agent for litigious and non-litigious matters |
Tel of Agent for litigious and non-litigious matters |
Address of Agent for litigious and non-litigious matters |
||||||
Wang Chiung Chih | 02-23252008 | 23F,No.76,Sec.2,Dunhua S.Road,Taipei,Taiwan 10683, ROC | ||||||
Industry | Main Business | |||||||
Biotechnology and Medical Care | Main products & outlook 1. Radiosurgery Tumor Treatment Medical Device 2. Clinical Diagnostic Applications & Products Cowealth was formed by a group of prominent biomedical professionals and businessmen with the aim of bringing advanced medical devices and technologies from all over the world into hospitals in greater china. We constantly source the world for advanced medical equipment and bring them to hospitals in greater china, but more than being just a dealer, Cowealth looks at itself more as a partner to equipment manufacturers and the hospitals it services, sharing their risks and complementing their strengths. Organization-wise, the company is structured to operate effectively as a bridge between its suppliers and its clients, with this strong focus, Cowealth’s customer and service networks have fully evolved based on what complement our partners best, making it an ideal partner for both hospitals and manufacturers it is today. |
Market Information ( 2024/05/03 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
7 | 23.60 | 23.50 | 23.60 | 0.10 | 7 | .00 | 668 | 0 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/05/03) |
TPEx measures adopted (2024/05/03) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |